1329 related articles for article (PubMed ID: 12621016)
1. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ
Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR
Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315
[TBL] [Abstract][Full Text] [Related]
5. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma.
Wiseman GA; Leigh B; Erwin WD; Lamonica D; Kornmehl E; Spies SM; Silverman DH; Witzig TE; Sparks RB; White CA
Cancer; 2002 Feb; 94(4 Suppl):1349-57. PubMed ID: 11877765
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
7. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
Wiseman GA; Leigh BR; Erwin WD; Sparks RB; Podoloff DA; Schilder RJ; Bartlett NL; Spies SM; Grillo-López AJ; Witzig TE; White CA
Cancer Biother Radiopharm; 2003 Apr; 18(2):165-78. PubMed ID: 12804042
[TBL] [Abstract][Full Text] [Related]
8. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.
Witzig TE
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S91-5. PubMed ID: 11587375
[TBL] [Abstract][Full Text] [Related]
10. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (
Wahl RL; Frey EC; Jacene HA; Kahl BS; Piantadosi S; Bianco JA; Hammes RJ; Jung M; Kasecamp W; He B; Sgouros G; Flinn IW; Swinnen LJ
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204102
[TBL] [Abstract][Full Text] [Related]
11. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
Cremonesi M; Ferrari M; Grana CM; Vanazzi A; Stabin M; Bartolomei M; Papi S; Prisco G; Ferrucci PF; Martinelli G; Paganelli G
J Nucl Med; 2007 Nov; 48(11):1871-9. PubMed ID: 17978355
[TBL] [Abstract][Full Text] [Related]
12. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
[TBL] [Abstract][Full Text] [Related]
13. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
Witzig TE
Drugs Today (Barc); 2004 Feb; 40(2):111-9. PubMed ID: 15045033
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice.
Hagenbeek A
Leuk Lymphoma; 2003; 44 Suppl 4():S37-47. PubMed ID: 15154741
[TBL] [Abstract][Full Text] [Related]
15. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).
Bischof Delaloye A
Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740
[TBL] [Abstract][Full Text] [Related]
16. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
Wiseman GA; Gordon LI; Multani PS; Witzig TE; Spies S; Bartlett NL; Schilder RJ; Murray JL; Saleh M; Allen RS; Grillo-López AJ; White CA
Blood; 2002 Jun; 99(12):4336-42. PubMed ID: 12036859
[TBL] [Abstract][Full Text] [Related]
17. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
18. Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy.
Wiseman GA; Leigh BR; Dunn WL; Stabin MG; White CA
Cancer Biother Radiopharm; 2003 Apr; 18(2):253-8. PubMed ID: 12804052
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
20. Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).
Chiesa C; Botta F; Coliva A; Maccauro M; Devizzi L; Guidetti A; Carlo-Stella C; Seregni E; Gianni MA; Bombardieri E
Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1745-57. PubMed ID: 19455328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]